Author pages are created from data sourced from our academic publisher partnerships and public sources.
Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer
- K. Schalper, D. Carvajal-Hausdorf, +7 authors D. Rimm
- Biology, Medicine
- Clinical Cancer Research
- 20 July 2016
Purpose: To determine the expression level, associations, and biological role of PD-L1, IDO-1, and B7-H4 in non–small cell lung cancer (NSCLC). Experimental Design: Using multiplexed quantitative… Expand
A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
Importance Assessment of PD-L1 (programmed cell death 1 ligand 1) expression by immunohistochemical analysis has been used as a predictive diagnostic test to identify responders and guide treatment… Expand
B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes
Purpose: The immune checkpoint PD-1 and its receptor B7-H1 (PD-L1) are successful therapeutic targets in cancer but less is known about other B7 family members. Here, we determined the expression… Expand
Measurement of spatial and antibody-based PD-L1 heterogeneity in non-small cell lung cancer.
9040Background: Assessment of PD-L1 is not yet standardized and is based largely on “assay performance” rather than protein measurement; with each assay requiring its own specialized platform and a...
PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus
PD-1H (VISTA) is immunosuppressive during lupus progression and could be targeted by an agonistic antibody for therapy. Supporting a suppressor for lupus treatment Autoimmunity can result when the… Expand
Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma
- James W Smithy, Lauren M. Moore, +7 authors D. Rimm
- Journal of Immunotherapy for Cancer
- 21 March 2017
BackgroundPredictive biomarkers for antibodies against programmed death 1 (PD-1) remain a major unmet need in metastatic melanoma. Specifically, response is seen in tumors that do not express… Expand
Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells
In pre-clinical studies, triple-negative breast cancer (TNBC) cells have demonstrated sensitivity to the multi-targeted kinase inhibitor dasatinib; however, clinical trials with single-agent… Expand
Met and HGF inhibition in triple-negative breast cancer cell lines.
1066 Background: Basal-like breast cancer (BLBC) is associated with high expression of c-Met. c-Met and its ligand HGF may be rational therapeutic targets for BLBC. We evaluated expression of c-Met… Expand
843 Immune checkpoint molecule PD-1H/VISTA expression correlates with melanoma survival
Preclinical evaluation targeting both IGF1R and IR in triple negative breast cancer
Abstract Background Insulin Receptor (INSR) signalling may play a role in resistance to insulin-like growth factor receptor (IGF1R) therapy. Although IGF1R is frequently expressed in triple negative… Expand